However, in the latest international guidelines [1–3], apoA-1 and the apoB/apoA-1 ratio are not mentioned, but apoB is recommended as an alternative risk marker to LDL-C or non-HDL-C in individuals with type 2 diabetes and in patients with hypertriglyceridaemia or obesity [4–6]. Here, APOB is linked to obesity due to melanocortin 4 receptor deficiency.